Sentence examples for synergy trial from inspiring English sources

The ongoing Zometa-Femara Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of zoledronic acid in preventing such bone loss.

Study Design The Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial is an 8000-patient, prandomized, randomized, open-label, multicenter investigation of enoxaparin comulticenter unfractinvestigationin in patients at high risk with nof-ST-senoxaparinvation Acompareded with an early invasive strategy.

Implications The SYNERGY trial is the largest study currently planned for the acute therapy of patients with non-ST-segment elevation ACS and the first large trial since the publication of the revised American College of Cardiology/American Heart Association guidelines for the management of these patients.

The Superior Yield of the New strategy of Enoxaparin, Revascularization, and GlYcoprotein IIb/IIIa inhibitors (SYNERGY) trial is a large-scale, randomized, controlled trial evaluating the effect of enoxaparin and unfractionated heparin on death and myocardial infarction in high-risk patients presenting with non ST-segment elevationon ST-segment

In the SYNERGY trial, patients received 12 weeks of sofosbuvir and ledipasvir (an NS5A inhibitor) or 6 weeks of sofosbuvir, ledipasvir, and GS-9669 or GS-9451.

87– 89 However, unlike in the SYNERGY trial, all detectable values at the end of treatment were preceded by undetectable measurements, 87– 89 which made them appear to be due to measurement errors.

In the Zometa-Femara Adjuvant Synergy Trials (Z-FAST/ZO-FAST/E-ZO-FAST), designed to investigate the bone-protective effects of zoledronic acid, an exploratory analysis was conducted to assess the anticancer potential of zoledronic acid.

In three Zometa-Femara Adjuvant Synergy Trials (Z-FAST, ZO-FAST, and E-ZO-FAST), patients received letrozole therapy combined with either immediate or delayed (that is, after a fracture or after BMD T-score decreased to -2.0) zoledronic acid treatment [ 23- 25].

Although preclinical data and an early clinical trial suggested synergy between gp100 vaccine and CTLA4 blockade [38], this could not be confirmed in this large RCT.

Based on potential drug synergy a phase II trial compared two experimental arms: MMC combined with biweekly high-dose gemcitabine vs MMC combined with capecitabine (Kornek et al, 2004).

Phase I and II studies using flavopiridol in combination with other agents utilizing the various schedules obtained mixed results, although partial and complete responses in these trials indicated potential synergy of flavopiridol with chemotherapy [15].